TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31183919

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's (LR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 0.9% Normal Saline (NS)
Number of subjects: 50
Study: 30326906

Group type: EXPERIMENTAL
Intervention: Self-management exercise program (5 sessions of 1.5 hours each) + information booklet + 18 sessions of spa therapy treatment (1 hour each)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information booklet + 18 sessions of spa therapy treatment (1 hour each)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-management exercise program + spa therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information booklet + spa therapy
Number of subjects: 0
Study: 27109450

Group type: EXPERIMENTAL
Intervention: Topiroxostat 120 mg/day
Number of subjects: 206

Group type: COMPARATOR
Intervention: Allopurinol 200 mg/day
Number of subjects: 206
Study: 25208075

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (n = 34)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Resistance exercise training (n = 28)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Aerobic + resistance exercise training (n = 13)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Detraining (following training)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Training responders
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Training non-responders
Number of subjects: 75
Study: 22166557

Group type: EXPERIMENTAL
Intervention: Balapiravir 500, 1000, or 1500 mg twice daily plus peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 516

Group type: COMPARATOR
Intervention: Peginterferon alfa-2a (40KD)/ribavirin
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Balapiravir
Number of subjects: 516

Group type: EXPERIMENTAL
Intervention: Balapiravir/peginterferon alfa-2a/ribavirin combination
Number of subjects: 516
Study: 20531106

Group type: EXPERIMENTAL
Intervention: Enema Casen (250 ml)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fleet Enema (133 ml)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both Enemas
Number of subjects: 45
Study: 18549372

Group type: EXPERIMENTAL
Intervention: In-clinic rescue therapy (maximum of 2 visits per month)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard therapy (optimal self‐administered medical therapy)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: In-clinic rescue therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 200
Study: 15909441

Group type: EXPERIMENTAL
Intervention: Cavilon No Sting Barrier Film (NSBF)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Zinc paste compound
Number of subjects: 35
Study: 12543286

Group type: EXPERIMENTAL
Intervention: Plasma chromogranin A levels (measured 3 days after onset of symptoms)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Elevated chromogranin A level (cutoff, 24 ng/mL)
Number of subjects: 119
Study: 10337883

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide and 50% oxygen
Number of subjects: 22

Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 22
Study: 8659316

Group type: EXPERIMENTAL
Intervention: Laparotomy by Pomeroy technique
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Laparoscopy by Fallope rings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Colpotomy by fimbriectomy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 43
Study: 2140382

Group type: EXPERIMENTAL
Intervention: Paroxetine (30 mg/day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day)
Number of subjects: 120
Study: 6993671

Group type: EXPERIMENTAL
Intervention: Benoxaprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 0
Study: 31640452

Group type: EXPERIMENTAL
Intervention: Office-based vergence/accommodative therapy (OBVAT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Office-based placebo therapy (OBPT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CI patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CI patients with comorbidity
Number of subjects: 100
Study: 31129930

Group type: EXPERIMENTAL
Intervention: ASP2205 10 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ASP2205 60 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 28730680

Group type: EXPERIMENTAL
Intervention: Cervical stability training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cervical-core stability training
Number of subjects: 50
Study: 25200949

Group type: EXPERIMENTAL
Intervention: Educational group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study: 24108780

Group type: EXPERIMENTAL
Intervention: EV71 vaccine (400 U of EV71 antigen)
Number of subjects: 1400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study: 21812557

Group type: EXPERIMENTAL
Intervention: Speech sounds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspeech mouth sounds (ingressive click)
Number of subjects: 0
Study: 19485588

Group type: EXPERIMENTAL
Intervention: Multifamily psychoeducation groups (MFPG)
Number of subjects: 165
Study: 17000352

Group type: EXPERIMENTAL
Intervention: Experimental silicon liner (VL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dummy liner (PL)
Number of subjects: 30
Study: 15592213

Group type: EXPERIMENTAL
Intervention: Bionator therapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (untreated Class II)
Number of subjects: 25
Study: 11115338

Group type: EXPERIMENTAL
Intervention: Bile leakage test (injection of isotonic sodium chloride solution through the cystic duct)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No bile leakage test (control group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Bile leakage test
Number of subjects: 103
Study: 9261307

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with single- or two-quadrant conjunctival peritomy
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 74

Group type: COMPARATOR
Intervention: Single- or two-quadrant conjunctival peritomy
Number of subjects: 74
Study: 7662225

Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: enalapril (20 mg/day)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: verapamil SR (240 mg/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: normotensive control subjects
Number of subjects: 39
Study: 2758384

Group type: EXPERIMENTAL
Intervention: Screening detected cancers
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Interval cancers
Number of subjects: 430

Group type: COMPARATOR
Intervention: Control group cancers
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Tumors with local recurrence
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Metastatic disease
Number of subjects: 430
Study: 322827

Group type: EXPERIMENTAL
Intervention: Live-attenuated A/Hong Kong/68 (H3N2) influenza vaccine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31977858

Group type: EXPERIMENTAL
Intervention: Vicagrel 40 to 75 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vicagrel 5 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 67
Study: 30940079

Group type: COMPARATOR
Intervention: 10 min algorithm
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Choi algorithm
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Troiano algorithm
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 30 min algorithm
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 60 min algorithm
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Concordance for MVPA assessment
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: 20 min algorithm
Number of subjects: 77
Study: 28187226

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 60 micrograms (2400 IU)/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Calcifediol (25D3) 20 μg/d
Number of subjects: 35

Group type: COMPARATOR
Intervention: Calcifediol (25D3)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 35
Study: 25584475

Group type: EXPERIMENTAL
Intervention: Enhanced training in Motivational Interviewing through an online learning community
Number of subjects: 0

Group type: COMPARATOR
Intervention: Training as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall sample (both groups)
Number of subjects: 0
Study: 25399616

Group type: EXPERIMENTAL
Intervention: AEC/soap-based cleanser
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual facial cleanser
Number of subjects: 30
Study: 21755327

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched tomato juice (500 mL daily, providing 250 mg of EPA and DHA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched tomato juice
Number of subjects: 18

Group type: COMPARATOR
Intervention: plain tomato juice
Number of subjects: 18
Study: 19663689

Group type: EXPERIMENTAL
Intervention: Nevirapine plus lopinavir-ritonavir (n = 34)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (lopinavir-ritonavir plus 2 NRTIs; n = 33)
Number of subjects: 67
Study: 17582564

Group type: EXPERIMENTAL
Intervention: Ty21a live oral typhoid vaccine (2 doses in Norte, 3 doses in Occidente)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ty21a live oral typhoid vaccine (pooled analysis)
Number of subjects: 0
Study: 15271236

Group type: EXPERIMENTAL
Intervention: Endovascular cooling device
Number of subjects: 153

Group type: COMPARATOR
Intervention: Surface convective air blanket
Number of subjects: 153
Study: 11588454

Group type: EXPERIMENTAL
Intervention: 40 mg iv omeprazole bolus injection (arm I)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 80 mg bolus followed by 8 mg/hr continuous infusion (arm II)
Number of subjects: 10
Study: 9337181

Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg/d
Number of subjects: 395

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 395
Study: 7902479

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 383

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study: 3510839

Group type: EXPERIMENTAL
Intervention: Tetracycline lavage
Number of subjects: 159

Group type: COMPARATOR
Intervention: Saline lavage
Number of subjects: 159
Study: 31693299

Group type: EXPERIMENTAL
Intervention: Differential fractional excretion of sodium (FeNa) derived from a morning void collection
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: INTERSALT equation
Number of subjects: 139
Study: 29407520

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study: 27584715

Group type: EXPERIMENTAL
Intervention: Matrix therapy agent (ReGeneraTing Agent [RGTA])
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyaluronic acid‐containing eyedrops, 0.1%
Number of subjects: 40
Study: 23954039

Group type: EXPERIMENTAL
Intervention: HOPES (Helping Older People Experience Success) intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 183
Study: 21652150

Group type: EXPERIMENTAL
Intervention: Intranasal spray of oxytocin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 20172127

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) pretreatment for 30 minutes each day for five consecutive days before surgery.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) pretreatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no EA pretreatment)
Number of subjects: 60
Study: 18271430

Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor (HBPM) plus usual care
Number of subjects: 34

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 34
Study: 16245966

Group type: EXPERIMENTAL
Intervention: Brinzolamide twice-daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Dorzolamide three times daily (Control)
Number of subjects: 58
Study: 12076696

Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg once daily for 7-14 days
Number of subjects: 243

Group type: COMPARATOR
Intervention: Amphotericin B 0.5 g thrice daily for 7-14 days
Number of subjects: 243
Study: 9527195

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 30 g alpha‐KG/hour after the operation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 22
Study: 7608318

Group type: EXPERIMENTAL
Intervention: Eptastigmine 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Eptastigmine 30 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2187791

Group type: EXPERIMENTAL
Intervention: Sulphaphenazole 1 g 12 hourly by mouth x 10 days
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Inj streptomycin 1 g intramuscularly daily with sulphaphenazole 1 g 12 hourly orally x 10 days
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: trimethoprim 200 mg 12 hourly by mouth x 7‐10 days
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: erythromycin 500 mg 6 hourly orally x 7‐10 days
Number of subjects: 136
Study: 7031187

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30813125

Group type: EXPERIMENTAL
Intervention: Device-guided rehabilitation combined with traditional techniques
Number of subjects: 67

Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation treatments (pursed lips breathing and abdominal breathing training)
Number of subjects: 67
Study: 28187506

Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (ART-naïve women)
Number of subjects: 0
Study: 26125924

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) in water during early postoperative period
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional perioperative treatment
Number of subjects: 300
Study: 23414174

Group type: EXPERIMENTAL
Intervention: Personal Concerns Inventory plus treatment as usual
Number of subjects: 76

Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 76
Study: 21717884

Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% fixed combination
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/Timolol 0.5% fixed combination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day
Number of subjects: 32
Study: 19366826

Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) in monotherapy or in combination with irinotecan
Number of subjects: 200
Study: 17190733

Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca-A)
Number of subjects: 2729

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I)
Number of subjects: 2729

Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 2729

Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group
Number of subjects: 2729

Group type: EXPERIMENTAL
Intervention: Less intensive BP-lowering group
Number of subjects: 2729
Study: 15014018

Group type: EXPERIMENTAL
Intervention: High-dose IFN-alpha 2b (HDI)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Observation (Obs)
Number of subjects: 2000
Study: 11245347

Group type: EXPERIMENTAL
Intervention: Combination vaccine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Associated administration
Number of subjects: 158
Study: 9758295

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid magnesium (CSF Mg+2) levels
Number of subjects: 96

Group type: COMPARATOR
Intervention: Serum magnesium (serum Mg+2) levels
Number of subjects: 96
Study: 7805677

Group type: EXPERIMENTAL
Intervention: 20 W to 40 W step increase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 20 W to 80 W step increase
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lactic acid concentration during ramp tests at exercise intensities > 160 W in supine position
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mean power at 4 mmol.l-1 [la-]b
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake relative to body mass
Number of subjects: 9
Study: 2647819

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol (180 micrograms, four times a day)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Albuterol powder (200 micrograms, four times a day)
Number of subjects: 204
Study: 31515190

Group type: EXPERIMENTAL
Intervention: ESPB (group B, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (group C, n = 40)
Number of subjects: 80
Study: 31512815

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation for 24 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28108189

Group type: EXPERIMENTAL
Intervention: Tailored Internet‐based safety decision aid
Number of subjects: 720

Group type: COMPARATOR
Intervention: Control website (typical safety information available online)
Number of subjects: 720
Study: 26467414

Group type: EXPERIMENTAL
Intervention: Adjunctive omega-3 fatty acid supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjunctive omega-3 fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omega-3 supplementation
Number of subjects: 0
Study: 23174499

Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (BDT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Brief supportive psychotherapy (BSP)
Number of subjects: 88
Study: 21932934

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of IPL and radio frequency (RF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated square)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IPL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: IPL+RF
Number of subjects: 40
Study: 18242894

Group type: EXPERIMENTAL
Intervention: Topical DHEA (1%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 20
Study: 16490538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14640494

Group type: EXPERIMENTAL
Intervention: SP plus chloroquine
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: SP plus paracetamol
Number of subjects: 175

Group type: COMPARATOR
Intervention: SP alone
Number of subjects: 175

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All SP-treated groups
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 175
Study: 10971385

Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 68
Study: 8855148

Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment (various doses)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: RIA (gamma)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 177

Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 177
Study: 1610422

Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 600 mg ranitidine
Number of subjects: 9

Group type: COMPARATOR
Intervention: pentagastrin (0.37 microgram/kg, 0.75 microgram/kg, 1.5 micrograms/kg)
Number of subjects: 9
Study: 6091521

Group type: EXPERIMENTAL
Intervention: Subcuticular Prolene
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Subcuticular Dexon
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Op‐Site wound closure adhesive membrane
Number of subjects: 102
Study: 30736030

Group type: EXPERIMENTAL
Intervention: Intraneural sensory feedback
Number of subjects: 1
Study: 29345848

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Therapist Guided Internet-based Self-help (GSH-I)
Number of subjects: 147
Study: 27521354

Group type: EXPERIMENTAL
Intervention: Wheeled knee walker
Number of subjects: 24

Group type: COMPARATOR
Intervention: Axillary crutches
Number of subjects: 24
Study: 24345793

Group type: EXPERIMENTAL
Intervention: Levothyroxine (300 μg/d)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Levothyroxine (for women)
Number of subjects: 62
Study: 22752591

Group type: EXPERIMENTAL
Intervention: Self-reported questionnaire items
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cluster of three self-reported items (distribution of pain below the knee, leg pain worse than back pain, feeling of numbness or pins and needles in the leg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 0
Study: 20633307

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 18595436

Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg for 5 days)
Number of subjects: 10
Study: 16199843

Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 1273

Group type: COMPARATOR
Intervention: Comparison/services-as-usual condition
Number of subjects: 1273
Study: 11863118

Group type: EXPERIMENTAL
Intervention: Oral etoposide 50 mg/m2 for 21 consecutive days every 4 weeks for three courses
Number of subjects: 144

Group type: COMPARATOR
Intervention: No further therapy (observation)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 144
Study: 10080231

Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (AP)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45